1.Cross talk between P2 purinergic receptors modulates extracellular ATP-mediated interleukin-10 production in rat microglial cells.
Dong Reoyl SEO ; Soo Yoon KIM ; Kyung You KIM ; Hwan Goo LEE ; Ju Hyun MOON ; Jae Souk LEE ; Se Hoon LEE ; Seung U KIM ; Yong Beom LEE
Experimental & Molecular Medicine 2008;40(1):19-26
Previously we demonstrated that ATP released from LPS-activated microglia induced IL-10 expression in a process involving P2 receptors, in an autocrine fashion. Therefore, in the present study we sought to determine which subtype of P2 receptor was responsible for the modulation of IL-10 expression in ATP-stimulated microglia. We found that the patterns of IL-10 production were dose-dependent (1, 10, 100, 1,000 micrometer) and bell-shaped. The concentrations of ATP, ATP-gammaS, ADP, and ADP-beta S that showed maximal IL-10 release were 100, 10, 100, and 100 micrometer respectively. The rank order of agonist potency for IL-10 production was 2'-3'-O-(4-benzoyl)-benzoyl ATP (BzATP) = dATP > 2-methylthio-ADP (2-meSADP). On the other hand, 2-methylthio-ATP (2-meSATP), alpha,beta-methylene ATP (alpha,beta-meATP), UTP, and UDP did not induce the release of IL-10 from microglia. Further, we obtained evidence of crosstalk between P2 receptors, in a situation where intracellular Ca2+ release and/or cAMP-activated PKA were the main contributors to extracellular ATP-(or ADP)-mediated IL-10 expression, and IL-10 production was down- regulated by either MRS2179 (a P2Y1 antagonist) or 5'-AMPS (a P2Y11 antagonist), indicating that both the P2Y1 and P2Y11 receptors are major receptors involved in IL-10 expression. In addition, we found that inhibition of IL-10 production by high concentrations of ATP-gammaS (100 micrometer) was restored by TNP-ATP (an antagonist of the P2X1, P2X3, and P2X4 receptors), and that IL-10 production by 2-meSADP was restored by 2meSAMP (a P2Y12 receptor antagonist) or pertusis toxin (PTX; a Gi protein inhibitor), indicating that the P2X1, P2X3, P2X4 receptor group, or the P2Y12 receptor, negatively modulate the P2Y11 receptor or the P2Y1 receptor, respectively.
Adenosine Diphosphate/analogs & derivatives/pharmacology
;
Adenosine Triphosphate/analogs & derivatives/*pharmacology
;
Adenylate Cyclase/antagonists & inhibitors
;
Animals
;
Calcium/metabolism
;
Chelating Agents/pharmacology
;
Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors
;
Enzyme Inhibitors/pharmacology
;
Extracellular Space/drug effects/*metabolism
;
Gene Expression Regulation/drug effects
;
Interleukin-10/*biosynthesis
;
Microglia/*drug effects/enzymology/*metabolism
;
RNA, Messenger/genetics/metabolism
;
Rats
;
Rats, Sprague-Dawley
;
Receptor Cross-Talk/*drug effects
;
Receptors, Purinergic P2/agonists/antagonists & inhibitors/genetics/*metabolism
;
Thionucleotides/pharmacology